Sivextro is approved for the treatment of acute bacterial skin infections, including those caused by methicillin-resistant Staphylococcus aureus.
The oral treatment option of the drug has been available since June, according to Rob Perez, president and COO of Cubist, but the I.V. version is newly available. “We believe the features and utility of Sivextro offers physicians an effective option to treat acute bacterial skin and skin structure infections in a number of real-life patient settings — from the hospital to the home,” he said in a news release.
More articles on MRSA:
10 recent stories, studies on MRSA
Changes in MRSA Treatment: 4 Trends
Methicillin-Susceptible S. aureus Strains a Concern in Neonatal Care Settings
